86 completed. 86 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 86 | Completed 86 |
| Phase 2 | 8 | Completed 8 |
Follow Hypercholesterolemia: new trials by email Literature Review of Hypercholesterolemia trials Research Report on Hypercholesterolemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C716 and C716R in Healthy Adults Test Drug, Reference Drug - Hypercholesterolemia, Dyslipidemia | Phase 1 | Completed | AJU Pharm Co., Ltd. | 41 | 2026-06-11 | 2026-07-10 |
| A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults AZD4954, Laroprovstat - Healthy Participants | Phase 1 | Completed | AstraZeneca | 31 | 2026-04-10 | 2026-08-04 |
| Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets Bempedoic acid film coated tablet, Nilemdo® Film-coated tablets - Hypercholesterolaemia | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 32 | 2025-05-21 | 2025-09-12 |
| To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C711 in Healthy Adults Test Drug, Reference Drug - Hypercholesterolemia | Phase 1 | Completed | AJU Pharm Co., Ltd. | 60 | 2025-03-29 | 2025-06-12 |
| Study of SHR-1209 Administered by Single-site or Multiple-site Subcutaneous Injections in Healthy Volunteers SHR-1209 single-site subcutaneous injection, SHR-1209 multiple-site subcutaneous injections - Hypercholesterolemia and Hyperlipidemia | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 49 | 2025-03-14 | 2026-07-30 |
| A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C. AZD0780, Ezetimibe, Rosuvastatin - Dyslipidemia | Phase 1 | Completed | AstraZeneca | 81 | 2024-12-20 | 2025-11-10 |
| Single Dose Oral Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets in Healthy Adult Human Subjects Under Fasting Conditions. Bempedoic Acid Film Coated Tablet, Nilemdo® (Bempedoic Acid) Film-coated tablets - Hypercholesterolaemia, Mixed Dyslipidaemia | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 14 | 2024-12-04 | 2025-04-11 |
| Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020) Enlicitide Decanoate - Hypercholesterolaemia | Phase 1 | Completed | Merck Sharp & Dohme LLC | 33 | 2023-07-20 | 2026-09-30 |
| A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin. AZD0780, Rosuvastatin - Dyslipidemia | Phase 1 | Completed | AstraZeneca | 16 | 2023-03-09 | 2025-04-27 |
| A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Administered IM in Adult Participants VXX-401, Placebo - Hypercholesterolemia | Phase 1 | Completed | Axxium Life, Inc. | 64 | 2023-03-07 | 2026-11-04 |
| A Study of MK-0616 in Healthy Adult Participants (MK-0616-009) MK-0616 - Hypercholesterolemia | Phase 1 | Completed | Merck Sharp & Dohme LLC | 24 | 2022-10-25 | 2024-09-19 |
| A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012) Enlicitide Chloride, Placebo - Healthy, Hypercholesterolemia | Phase 1 | Completed | Merck Sharp & Dohme LLC | 56 | 2022-09-30 | 2024-10-23 |
| A Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1018-1 and BR1018-2 in Healthy Adult Subjects BR1018-1, BR1018-2 - Hypertension, Hyperlipidemia (E.G., Hypercholesterolemia) | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 36 | 2022-08-04 | 2023-05-24 |
| A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease VERVE-101 - Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease | Phase 1 | Completed | Verve Therapeutics, Inc. | 13 | 2022-07-05 | 2025-05-08 |
| Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers SHR-1209 - Hypercholesterolemia and Hyperlipidemia | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 159 | 2022-05-25 | 2023-01-12 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects AZD0780, Placebo, Rosuvastatin - Dyslipidemia | Phase 1 | Completed | AstraZeneca | 183 | 2022-05-18 | 2026-09-09 |
| A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II NNC0385-0434 G, NNC0385-0434 F, NNC0385-0434 B - Healthy Volunteers; High Cholesterol | Phase 1 | Completed | Novo Nordisk A/S | 152 | 2022-04-12 | 2024-07-12 |
| A Research Study Looking at the Effect of Food Intake on How the Medicine NN0385-0434 Behaves in the Body of Healthy Participants NNC0385-0434 - Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk, Elevated Cholesterol | Phase 1 | Completed | Novo Nordisk A/S | 73 | 2021-12-09 | 2023-12-26 |
| Multiple Ascending Dose Study to Evaluate the Safety, Tolerability of DC371739 Treatment in Hypercholesterolemic DC371739 Tablets, Placebo - Hypercholesterolemia | Phase 1 | Completed | Guangzhou JOYO Pharma Co., Ltd | 51 | 2021-04-01 | 2022-03-16 |
| A Research Study Investigating How NNC0385-0434 is Tolerated in People With or Without High Cholesterol Levels NNC0385-0434, Placebo (NNC0385-0434) - Healthy Volunteers, Hypercholesterolaemia | Phase 1 | Completed | Novo Nordisk A/S | 39 | 2019-08-20 | 2021-12-30 |
Showing 20 of 86. Sign in to see all of them.
Dyslipidemias (15) · Hyperlipidemias (11) · Hypertension (5) · Cardiovascular Diseases (4) · Atherosclerosis (3) · Diabetes Mellitus (3) · Lipid Metabolism Disorders (3) · Metabolic Diseases (3) · Aneurysm (2) · Hypercholesterolemia, Autosomal Dominant, 3 (2) · Hyperlipoproteinemia Type II (2) · Hypertriglyceridemia (2) · Medication Adherence (2) · Obesity (2)
Nutritional and Metabolic Diseases (86) · Lipid Metabolism Disorders (83) · Metabolic Diseases (83) · Hyperlipidemias (75) · Dyslipidemias (71) · Vascular Diseases (7) · Cardiovascular Diseases (6) · Endocrine System Diseases (4) · Glucose Metabolism Disorders (4) · Arterial Occlusive Diseases (3) · Arteriosclerosis (3) · Behavior (3) · Body Weight (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2)
alirocumab (10) · Ezetimibe (8) · Atorvastatin (6) · bococizumab (6) · Rosuvastatin Calcium (5) · Simvastatin (4) · 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (3) · MK-0616 (3) · gemcabene (3) · Drug Evaluation (2) · Niacin (2) · ALN-PCS (1) · Adjuvants, Pharmaceutic (1) · Cytokines (1) · Ezetimibe, Simvastatin Drug Combination (1)
Sanofi (9) · Pfizer (8) · Merck Sharp & Dohme LLC (6) · AstraZeneca (5) · Jiangsu HengRui Medicine Co., Ltd. (3) · NeuroBo Pharmaceuticals Inc. (3) · Novartis Pharmaceuticals (3) · Novo Nordisk A/S (3) · Organon and Co (3) · AJU Pharm Co., Ltd. (2) · GlaxoSmithKline (2) · Humanis Saglık Anonim Sirketi (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (2) · University Medicine Greifswald (2)
United States (34) · China (8) · United Kingdom (8) · Germany (4) · Australia (3) · Canada (3) · France (3) · India (3) · South Korea (3) · Belgium (2) · Austria (1) · Brazil (1) · Israel (1) · Japan (1) · Moldova (1)
Werner Siegmund, Prof (2) · Adrian Di Bisceglie, MD,FACP,FAASLD (1) · Brad West, ND (1) · David Burger (1)
PMID 37994400, PMID 28181260, PMID 40587053, PMID 15324521, PMID 18068514, PMID 19500003, PMID 19833861, PMID 19843338, PMID 20457158, PMID 21120461, PMID 21417623, PMID 22435370, PMID 25256660, PMID 25942458, PMID 26607938, PMID 27184170, PMID 27287699, PMID 27959715, PMID 27986651, PMID 28636184, PMID 29037448, PMID 30243503, PMID 32080823, PMID 33183320, PMID 33969434, PMID 35427476, PMID 40252193, PMID 42137960
2015 (1), 2019 (1)